Metabolic Diseases  >>  anacetrapib (MK-0859)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
anacetrapib (MK-0859) / Merck (MSD)
NCT00565292: A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)

Completed
1
50
US
MK0859
Merck Sharp & Dohme LLC
Hypercholesterolemia, Hyperlipidemia
08/06
08/06
NCT01114490: Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)

Completed
1
24
US
anacetrapib
Merck Sharp & Dohme LLC
Dyslipidemia
07/10
07/10
NCT00990808: The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

Checkmark ATVB 2013: Effect of anacetrapib treatment on CETP metabolism
May 2013 - May 2013: ATVB 2013: Effect of anacetrapib treatment on CETP metabolism
Checkmark Data
Apr 2012 - Apr 2012: Data
Completed
1
46
US
anacetrapib, Comparator: atorvastatin, Comparator: placebo to MK0859, Comparator: placebo to atorvastatin
Merck Sharp & Dohme LLC
Dyslipidemia
06/11
07/11
NCT01122667: Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)

Completed
1
24
US
anacetrapib
Merck Sharp & Dohme LLC
Dyslipidemia
06/11
06/11

Download Options